Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20176363 | 0.85 | AAK1 (0.51) | AAK1ROCK2MAPT | |
| SCHEMBL15240866 | 0.82 | ROCK2 (0.40) | AAK1ROCK2MAPTRXFP1THRB | |
| SCHEMBL19946044 | 0.82 | AAK1 (0.38) | AAK1HTR2BROCK2MAPTRXFP1 | |
| SCHEMBL19946090 | 0.82 | AAK1 (0.54) | AAK1HTR2BROCK2MAPTRXFP1 | |
| SCHEMBL20176364 | 0.80 | AAK1 (0.60) | AAK1ROCK2MAPTSMN1; SMN2 | |
| SCHEMBL19946145 | 0.78 | ROCK2 (0.51) | AAK1ROCK2 | |
| SCHEMBL19946106 | 0.77 | AAK1 (0.60) | AAK1ROCK2 | |
| SCHEMBL19946104 | 0.76 | ROCK2 (0.56) | AAK1ROCK2 | |
| SCHEMBL15430125 | 0.75 | HTR2B (0.43) | HTR2BROCK2MAPTPGRAR | |
| SCHEMBL20176331 | 0.75 | AAK1 (0.62) | AAK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141956-A1 | FUSED PYRIDINES AS KINASE INHIBITORS | AAK1, NCK1, ADCK1 | AAK1 1/4885HTR2B 4678/4885ROCK2 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.